The vaccine, ID93/GLA-SE contains fusion protein of four antigens and a synthetic adjuvant formulation, which together enable T-cells to induce effective immunity and protect against TB
ID93/GLA-SE will be evaluated for its safety and immunogenicity in a group of healthy subjects.
The vaccine demonstrated protection against the tuberculosis microbe, Mycobacterium tuberculosis, both with and without boosting of BCG, in preclinical studies.
The trial is expected to begin in early 2012.